Sunshine Nuohe announced that the phase I clinical trial independently developed by STC008 injection to treat cachexia in advanced solid tumor tumors, a wholly-owned subsidiary of Nuohe Shengtai, has achieved the expected goals. The study showed that there were no serious adverse events in any dose group. The peak GH concentration reached 16 to 26 times that of the placebo group, and the net IGF-1 increase rate was 10.14% to 41.00%; the company is proceeding with preparations for phase II clinical trial plan design, ethical declaration, and clinical center screening in an orderly manner.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.